Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Botulinum toxin A - Allergan/Medytox

Drug Profile

Botulinum toxin A - Allergan/Medytox

Alternative Names: Botulift; Cunox; Innotox; KbtxA; Liquid-type botulinum toxin type A - Allergan; MBA-P01; Meditoxin; MT 10107; MT 10109; MT10109L; Neuronox; NivobotulinumtoxinA; Siax

Latest Information Update: 16 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medy-Tox
  • Developer Allergan; Medytox
  • Class Analgesics; Anti-inflammatories; Antiarrhythmics; Antidepressants; Antimigraines; Antispasmodics; Bacterial proteins; Bacterial toxins; Botulinum toxins; Eye disorder therapies; Foot disorder therapies; Muscle relaxants; Skin disorder therapies; Urologics
  • Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Membrane transport protein modulators; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Blepharospasm; Equinus foot deformity; Glabellar lines; Muscle spasticity; Spasm
  • Phase III Facial wrinkles; Hyperhidrosis; Hypertrophy; Overactive bladder; Torticollis

Most Recent Events

  • 25 Oct 2019 Phase-III clinical trials in Facial wrinkles in United Kingdom, Scotland, Russia, Germany, Belgium (Injection) (NCT04157686; EudraCT2014-005303-24)
  • 25 Oct 2019 Phase-III clinical trials in Glabellar lines in United Kingdom, Scotland, Germany, Belgium (IM) (NCT04157686; EudraCT2014-005303-24)
  • 23 Aug 2019 Phase-III clinical trials in Overactive bladder in South Korea (Parenteral, Injection) (NCT04113941)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top